VGX-1027

• UNSPSC Description:

  VGX-1027 is an orally active isoxazole compound that exhibits various immunomodulatory properties. VGX-1027 targets macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, IL-10. VGX-1027 has antidiabetogenic effects by limiting cytokine-mediated immunoinflammatory events[1][2][3].

• Target Antigen:

  Interleukin Related; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/VGX-1027.html

• Solubility:

  DMSO : ≥ 56 mg/mL

• Smiles:

  O=C(O)CC1CC(C2=CC=CC=C2)=NO1

• Molecular Weight:

  205.213

• References & Citations:

  [1]Stosic-Grujicic S, et al. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J Pharmacol Exp Ther. 2007 Mar;320(3):1038-49.|[2]Danijela Maksimovic-Ivanic, et al. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol Cancer Ther. 2008 Mar;7(3):510-20.|[3]K Mangano, et al. Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. Br J Pharmacol. 2008 Nov;155(5):722-30.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 1

• CAS Number:

  6501-72-0